Bone Density on GLP-1s: Do Men Over 50 Lose Bone Along With the Fat?
Probably some, yes. Losing a lot of weight tends to cost some bone along with the fat, and small trials of semaglutide and liraglutide have measured modest drops in hip and spine bone density. The best evidence on how to limit it comes from a 2024 trial where pairing liraglutide with structured exercise left bone density no different from placebo, while the drug alone did not. Data in men over 50 specifically are thin, which is a reason to ask about a DXA scan rather than assume.
Key takeaways
- In a 2024 randomized trial (JAMA Network Open), liraglutide alone lowered hip and spine bone density versus placebo; liraglutide plus exercise did not differ significantly from placebo, with the most weight loss of any group.
- A 2024 phase 2 trial of semaglutide 1.0 mg in adults at higher fracture risk found lower hip and spine bone density after 52 weeks, but only 9 of its 64 participants were men.
- The Endocrine Society's guideline for men says age 70 alone justifies a bone density test, and men 50 to 69 should be tested if they have other risk factors. The USPSTF says evidence is insufficient to judge routine screening in men.
- In the TRAVERSE substudy, testosterone gel did not lower fracture risk in hypogonadal men; fractures were more common than on placebo.
- Weight-bearing exercise, enough calcium and vitamin D, and a DXA of the hip and spine are the practical levers to discuss with your clinician.
Why weight loss affects bone at all
Bone responds to load. Carry less weight and the skeleton gets less mechanical signal to maintain itself, so bone density often falls during significant weight loss whatever the method. The 2024 trial discussed below was designed partly because this effect is a known concern with diet-induced weight loss (Jensen et al., JAMA Network Open 2024).
A single-center retrospective study published in 2026 in the Journal of Clinical Endocrinology and Metabolism looked at real-world patients. It matched 255 adults on semaglutide or tirzepatide with 255 non-users. Over a median of 17 months, both groups lost a similar amount of total hip and femoral neck bone density overall. In people without diabetes, though, total hip bone density fell more on the drugs: a median 1% versus 0.6% in non-users (Liu et al., JCEM 2026). Users were 92% women, so it says little directly about men.
For men, this matters because fractures hit harder than many expect. The NIH's bone institute notes that men who break a hip are more likely than women to have complications and to die as a result, and lists low testosterone, glucocorticoid use, smoking, heavy drinking, weak muscles and age 70 or older among men's risk factors (NIAMS, Osteoporosis in Men).
The key trial: liraglutide, exercise, or both
The clearest data on protecting bone during GLP-1 weight loss come from a Danish randomized trial. Adults aged 18 to 65 with obesity and no diabetes first lost weight on an 8-week, roughly 800-calorie diet. The 195 people who lost at least 5% were then randomized for 52 weeks to placebo, structured exercise, liraglutide 3.0 mg daily, or liraglutide plus exercise. The exercise program centered on vigorous sessions, with group and individual workouts each scheduled twice a week (Jensen et al., JAMA Network Open 2024).
| Arm (52 weeks after the diet) | Hip BMD vs. placebo (g/cm²) | Spine BMD vs. placebo (g/cm²) | Statistically different? |
|---|---|---|---|
| Exercise alone | −0.001 | −0.002 | No |
| Liraglutide alone | −0.013 | −0.019 | Yes, lower at both sites |
| Liraglutide + exercise | −0.006 | −0.010 | No |
Source: Jensen SBK et al., JAMA Netw Open 2024;7(6):e2416775. BMD = bone mineral density.
The combination group lost the most weight, 16.88 kg from the start of the study versus 7.03 kg on placebo, yet its bone density was not significantly different from placebo. Liraglutide alone lowered hip and spine density more than exercise alone despite similar weight loss. That points to exercise, not just the amount of weight lost, as a major factor in what happens to bone.
The fine print
- The trial was powered for weight, not bone. Bone density was a secondary analysis, with data for about 81% to 83% of participants at week 52.
- "Not significantly different" is not the same as "no bone loss." The confidence intervals for the combination group still allow a meaningful decline.
- Participants averaged about 43 years old and 64% were women; 71 were men. It is not a trial of men over 50.
- It used liraglutide, an older daily GLP-1. Whether the same holds for semaglutide or tirzepatide has not been tested the same way.
What we know about semaglutide and tirzepatide
The main randomized semaglutide bone study is a Danish phase 2 trial published in eClinicalMedicine in 2024. It gave 64 adults at increased fracture risk (low bone density or a recent low-energy fracture) weekly semaglutide 1.0 mg or placebo for 52 weeks. Mean age was 63, and 9 participants were men (Hansen et al., eClinicalMedicine 2024).
Semaglutide did not change its primary target, a marker of bone formation. But a marker of bone breakdown rose, and bone density fell versus placebo at the lumbar spine (−0.018) and total hip (−0.020), with no significant difference at the femoral neck. The semaglutide group also lost 6.8 kg more than placebo. The authors suggest the weight loss may explain the rise in bone breakdown.
For tirzepatide, the bone data cited here come from the 2026 observational study above, which pooled semaglutide and tirzepatide users. Body-composition coverage of the big weight-loss trials has centered on fat and lean mass, which our muscle-focused guides cover. Bone needs its own question at your visit.
On fractures, a 2026 systematic review published by the American Osteopathic Academy of Orthopedics concluded that "current evidence does not support a consistent reduction in fracture risk" with GLP-1 drugs (AOAO systematic review, 2026). It does not show they raise fracture risk either. The question is still open.
| Study | Drug | Who | Bone finding |
|---|---|---|---|
| Jensen 2024 (RCT, 52 wk) | Liraglutide 3.0 mg ± exercise | 195 adults, 36% men, mean age 43 | Drug alone lowered hip and spine BMD; combo not different from placebo |
| Hansen 2024 (phase 2 RCT, 52 wk) | Semaglutide 1.0 mg | 64 adults at fracture risk, 9 men, mean age 63 | Lower hip and spine BMD vs. placebo; more bone breakdown |
| Liu 2026 (retrospective) | Semaglutide or tirzepatide | 255 users vs. 255 matched non-users; users 92% women, mean age 64 | Similar hip loss to matched non-users overall; −1% vs. −0.6% hip in non-diabetics |
Source: Jensen 2024; Hansen 2024; Liu 2026.
Weighing a GLP-1 after 50?
Compare participating telehealth providers and check each one's terms; a consult is not a prescription guarantee.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Should men over 50 get a DXA scan?
The guidance differs by group. The Endocrine Society's clinical practice guideline on osteoporosis in men states that "age 70 is a sufficient risk factor" for bone density testing and that men aged 50 to 69 "should be tested if additional risk factors are present." It recommends DXA of the spine and hip (Watts et al., Endocrine Society guideline, JCEM 2012).
The US Preventive Services Task Force, in its January 2025 update, recommends screening for women 65 and older and younger postmenopausal women at increased risk. For men, it issued an "I statement," meaning the evidence is insufficient to weigh benefits and harms of routine screening. The Task Force notes this is not a recommendation against screening (USPSTF, Osteoporosis Screening, 2025).
| Group | Endocrine Society (men) | USPSTF |
|---|---|---|
| Men 70+ | Test; age alone is enough | Insufficient evidence (I statement) |
| Men 50 to 69 | Test if other risk factors present | Insufficient evidence (I statement) |
| Women 65+ | Not covered | Screen (Grade B) |
| Preferred test | DXA of spine and hip | Not applicable to men |
Source: Endocrine Society 2012; USPSTF 2025.
Rapid, large weight loss is not listed as a screening trigger in either document. Still, a man in his 50s or 60s with other risk factors who is losing weight quickly has a reasonable case for asking. If you are already getting a DXA for body composition, ask whether the hip and spine can be read for bone density in the same visit. A body-composition scan and a diagnostic bone density exam are not always the same test.
Testosterone, TRT and bone
Low testosterone is a recognized bone risk factor in men (NIAMS). The 2012 Endocrine Society guideline suggests testosterone therapy instead of a bone drug for some men at borderline-high fracture risk who have repeatedly low testosterone and symptoms. It says men at high fracture risk should get a drug with proven fracture benefit, such as a bisphosphonate (Endocrine Society).
Newer evidence complicates the assumption that TRT protects bone. In a substudy of the TRAVERSE trial, 5,204 hypogonadal men aged 45 to 80 were randomized to testosterone gel or placebo gel. Over a median of 3.19 years, fractures occurred in 3.50% on testosterone versus 2.46% on placebo, a hazard ratio of 1.43 (Snyder et al., NEJM 2024). The trial was not designed to explain why. The takeaway for men on a GLP-1 plus TRT: do not count on testosterone to cover bone.
Exercise, calcium and vitamin D
The Jensen trial is the strongest argument that exercise matters during GLP-1 weight loss. The Endocrine Society guideline separately suggests weight-bearing activity for 30 to 40 minutes per session, three to four sessions a week, for men at risk of osteoporosis.
For nutrition, the NIH Office of Dietary Supplements sets calcium at 1,000 mg a day for men 51 to 70 and 1,200 mg for men 71 and older (NIH ODS, Calcium). Vitamin D is 600 IU (15 mcg) a day through age 70 and 800 IU (20 mcg) from 71 (NIH ODS, Vitamin D). The Endocrine Society prefers calcium from food, with supplements only to fill a gap, and suggests vitamin D supplements for men with low blood levels.
Questions to bring to your clinician
- Given my age and risk factors, do I meet the Endocrine Society criteria for a DXA bone density test?
- If I'm getting a body-composition scan, will it report hip and spine bone density, or is that a separate exam?
- Should my exercise plan include resistance and weight-bearing work, and how much?
- Am I getting enough calcium and vitamin D on my reduced intake? Should we check a vitamin D level?
- If I'm on TRT, how does the TRAVERSE fracture finding apply to me?
Where this guide stops
The bone data on GLP-1s are small, short and mostly in women. None of the trials here studied men over 50 as their own group, and none were long enough to count fractures. This guide does not tell you whether you need a bone drug; that depends on your scan, history and fracture risk.
Key takeaway: Expect weight loss to cost some bone, plan exercise as the main defense, and ask whether your age and risk factors call for a hip and spine DXA.
Compare available care options
See participating providers' current pricing and terms; eligibility is decided by a licensed clinician.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Do GLP-1 drugs cause bone loss?
Weight loss tends to lower bone density, and small trials found modest drops at the hip and spine with liraglutide alone and with semaglutide 1.0 mg versus placebo. No trial has shown whether this changes fracture risk.
Does exercise protect bone on a GLP-1?
In a 2024 JAMA Network Open trial, liraglutide plus structured exercise left hip and spine bone density not significantly different from placebo, while liraglutide alone lowered it. The trial was not powered for bone and some decline cannot be ruled out.
Should men over 50 get a DXA bone density scan?
The Endocrine Society guideline says men 70 and older should be tested and men 50 to 69 should be tested if they have other risk factors. The USPSTF says evidence is insufficient to judge routine screening in men, which is not a recommendation against it.
Does testosterone therapy protect bones?
Not reliably. In the TRAVERSE fracture substudy of 5,204 hypogonadal men, fractures occurred in 3.50% on testosterone gel versus 2.46% on placebo over a median of 3.19 years.
How much calcium and vitamin D do men over 50 need?
NIH lists calcium at 1,000 mg a day for men 51 to 70 and 1,200 mg from 71, and vitamin D at 600 IU through age 70 and 800 IU from 71.
Sources
- Jensen SBK et al. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment. JAMA Netw Open 2024;7(6):e2416775
- Hansen MS et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised phase 2 trial. eClinicalMedicine 2024;72:102624
- Liu Y et al. Skeletal Effect of Semaglutide and Tirzepatide in Patients with Increased Risk of Fractures. J Clin Endocrinol Metab 2026
- The Effect of GLP-1 Receptor Agonists on Bone Health: A Systematic Review. AOAO, 2026
- Watts NB et al. Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822
- USPSTF: Osteoporosis to Prevent Fractures: Screening (January 2025)
- NIAMS: Osteoporosis in Men
- Snyder PJ et al. Testosterone Treatment and Fractures in Men with Hypogonadism. N Engl J Med 2024;390(3):203-211
- NIH Office of Dietary Supplements: Calcium fact sheet
- NIH Office of Dietary Supplements: Vitamin D fact sheet
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.